Trial
NCT01275287
Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of North Carolina, Chapel Hill
Collaborators
Alexion Pharmaceuticals, Inc.; National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Condition
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Intervention
Standard of care treatment
Why stopped
the study failed to enroll any patient and sponsor wished to stop.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-02-23